ANH Plus Cell Salvage: Extra Blood Sparing in Major Orthopedics?
Allogeneic transfusion is still part of many big orthopedic cases, even when cell salvage is available. A single-center randomized trial published September 25, 2026 in BMC Anesthesiology asked whether adding acute normovolemic hemodilution (ANH) to intraoperative cell salvage (ICS) cuts transfusion further than ICS alone.
The study
Sixty adults having elective major orthopedic surgery were randomized 1:1 to ANH plus ICS or ICS alone. The primary outcome was total perioperative allogeneic red cell transfusion volume. Secondary outcomes covered intraoperative and postoperative transfusion rates, hemoglobin trends, coagulation labs, cost, and safety signals such as hypotension and vasopressor use.
Perioperative allogeneic RBC volume was lower with the combined strategy (median 0 U, IQR 0 to 1) than with ICS alone (median 1 U, IQR 0 to 3.25; P = 0.006). Postoperative transfusion fell from 60% to about 23% (absolute risk reduction 36.7%, number needed to treat about 2.7). Intraoperative transfusion did not differ much. Hemoglobin stayed higher in the ANH plus ICS group. Coagulation measures, hypotension, and vasopressor needs looked similar. Transfusion-related costs were lower with the combination.
Why it makes sense
ANH banks the patient's own whole blood before major loss, and ICS returns shed red cells during the case. Using both is not a new idea, but good randomized data in orthopedic surgery are still limited. In this small trial the extra benefit showed up mainly after surgery, which fits a picture where early salvage covers the OR and banked ANH blood helps later when drip and labs catch up.
What it means for practice here
For high-blood-loss orthopedic lists where ICS is already planned, adding carefully done ANH may be worth a fresh look if staffing and timing allow. This was 60 patients at one center, so I would not rewrite a whole pathway off one paper. Patient selection, starting hematocrit, how much blood is removed, and how transfusion triggers are applied all matter. Safety looked reassuring here, but ANH still needs a team that is comfortable with the logistics.
Bottom line for me: ICS remains a workhorse. ANH on top of it may spare more allogeneic units in the right orthopedic patients, and this trial is a useful nudge to audit our own transfusion numbers rather than assume salvage alone is doing all it can.
Source
- Jin L, Gu X, Lei G, Gu Y, Jiang L. Synergistic blood-sparing effect of acute normovolemic hemodilution combined with intraoperative cell salvage in major orthopedic surgery: a randomized controlled trial. BMC Anesthesiology. 2026. Published September 25, 2026. Article (BMC Anesthesiology)
This post is clinician commentary for educational discussion. It is not medical advice for any reader's personal care. Anesthesia and perioperative decisions should be made with the treating clinician based on the individual patient's circumstances.